Caren van Roekel

149 Mode of progression after radioembolization in colorectal cancer patients The difference in response evaluation was compared for patients with or without extrahepatic metastases at baseline. Of the group (n=42, 47%) presenting with extrahepatic metastases at baseline, 93% was diagnosed with PD at three- months follow-up. Significantly fewer patients (63%) were diagnosed with progressive disease in the group of patients (n=48, 53%) presenting without extrahepatic metastases at baseline (p=0.0017) (Table 3). TABLE 3. RECIST 1.1 response classification at 3-months post-treatment Total No extrahepatic metastases at baseline 48(53%) Complete response 0 (0%) Partial response 5 (10%) Stable disease 13 (27%) Progressive disease 30 (63%) Extrahepatic metastases at baseline 42 (47%) Complete response 0 (0%) Partial response 0 (0%) Stable disease 3 (7%) Progressive disease 39 (93%)* Yttrium-90 Resin No extrahepatic metastases at baseline 28(61%) Complete response 0 (0%) Partial response 1 (4%) Stable disease 7 (25%) Progressive disease 20 (71%) Extrahepatic metastases at baseline 18 (39%) Complete response 0 (0%) Partial response 0 (0%) Stable disease 2 (11%) Progressive disease 16 (89%) Yttrium-90 Glass No extrahepatic metastases at baseline 9 (45%) Complete response 0 (0%) Partial response 2 (22%) Stable disease 2 (22%) Progressive disease 5 (56%) Extrahepatic metastases at baseline 11 (55%) Complete response 0 (0%) Partial response 0 (0%) 5